One pharmaceutical firm is gearing up for the production of Covid19 vaccines here in the Philippines.
Glovax Biotech, according to reports, is currently engaged in talks with the Department of Trade and Industry and the Board of Investments as it is interested in putting up a production plant for “next generation” Covid19 vaccines.
In a statement, Glovax representatives say the company is ready to invest P7 billion for the construction of the facility as well as the transfer of technology costs should the Philippine government sign a letter of intent to order 40 million doses of the vaccine.
Glovax is entering into a partnership with the South Korean firm Eugiologics to locally produce EuCorVac-19 which was developed in the US by POP Biotechnologies.
The EuCorVac-19 vaccine is to be initially produced and marketed in South Korea before distribution to other countries like the Philippines.
Aside from EuCorVac-19, Glovax is planning to link up with another South Korean company, LG Chem, to produce vaccines for diphtheria, tetanus, pertussis, Hepatitis-B and Haemophilus influenza-B.
It was stressed that Glovax is no stranger to the Philippines, having sold some five million doses of vaccines for polio, TB, measles, tetanus and rabies since 2003.